Neuropeptide Receptor Group
Our group studies G protein-coupled receptors (GPCRs) which represent the most important class of biomolecules for pharmaceutical development, being targeted by ~30 per cent of current drugs.
Our studies on the structure and function of novel neuropeptide GPCRs will enable the development of new drugs to specifically target neurological and other diseases.
About our research
- Drug discovery and development
- A new chemogenetic method that enables functional neural circuit analysis
- Drug discovery: investigation of signalling by GPCRS using novel cellular biosensors
- Peptidomimetic drug design targeting G protein-coupled receptors
- Targeting peptide G protein-coupled receptors (GPCRs) for novel drug development
Research and technical staff
- Tania Ferraro
- Sharon Layfield
- Yasmin Potts
- Alice Whitehead
- Andy Zhang
- Theingi (Tiffany) Myint
- Renate Roeterink
- Jonathan Sher
- Xintong Zheng
- Eleanor Gillies
- Hossain, M.A. and Bathgate, R.A.D. (2018). Challenges in the design of insulin and relaxin/insulin-like peptide mimetics. Bioorganic & Medicinal Chemistry, [online] 26(10), pp.2827–2841. doi:https://doi.org/10.1016/j.bmc.2017.09.030.
- Valkovic, A.L., Kocan, M., Hoare, B., Marshall, S., Scott, D.J. and Bathgate, R.A.D. (2022). A Real-Time, Plate-Based BRET Assay for Detection of cGMP in Primary Cells. International Journal of Molecular Sciences, [online] 23(3), p.1908. doi:https://doi.org/10.3390/ijms23031908.
- Bathgate, R.A.D., Kocan, M., Scott, D.J., Hossain, M.A., Good, S.V., Yegorov, S., Bogerd, J. and Gooley, P.R. (2018). The relaxin receptor as a therapeutic target – perspectives from evolution and drug targeting. Pharmacology & Therapeutics, [online] 187, pp.114–132. doi:https://doi.org/10.1016/j.pharmthera.2018.02.008.